Chirfi Guindo

Do you know Dave Ford ? I first met him about 20 years ago when I was at Sanofi. It was a time, on reflection, filled with incredible talented people, people who have proven over years how outstanding they are. It was a powerful, important time in my career, when I learned quickly and when I was given opportunities to stretch myself by people who were courageous enough to let me have a go and who were confident that talent and hard work were more important than experience. For fun, I found a photo from back in those days - looking fresh faced! I remember when David was a new HR Director talking about the new car policy - something very important to the sales team!! He talked about the new flexible policy where options were allowed - you could bespoke your car - life changing for some people at that time - but David gave a condition - “Except if you want to add a whales tail fin to the back!” It summed him up. He knew the audience, he was humourous, fun, but also very strategic about his thinking. I was immediately impressed. I knew that when we decided to run a series on The Commercial Edge Podcast on difficult conversations I wanted David to join the conversation. We have stayed in touch over the years through social media and he was generous enough to debut his podcast career with us. He didn’t disappoint! We talked company values, communicating change, consistency in messages, honesty and transparency. It is a typical David discussion, smart, considered, strategic - all the reasons why he continues to shape businesses for the better. Have a listen on Spotify, Apple Podcasts, Podbean or where you get your podcasts. https://lnkd.in/eYpY4QB7

90

37 Comments

Urgent action is needed to change the mindset on health investment. Most households in Sub-Saharan Africa (SSA) are one disease away from poverty (1).  It is an undeniable truth that healthcare remains a pressing issue in Sub-Saharan Africa (SSA). The region bears a disproportionate burden of disease yet limited resources are allocated to tackle this crisis. Picture this: SSA accounts for just 1% of global healthcare spending but shoulders 25% of the world's disease burden. Exacerbating this predicament, out-of-pocket spending poses a major challenge, placing a heavy load on individuals and families, especially in low-income communities. This certainly necessitates prompt action. Shifting the perception that investing in health is a burden on public finances requires a multi-faceted approach involving education, communication, policy changes, and collaboration. At its core, strong leadership and political will are imperative for driving transformative change in healthcare financing and access. Two decades on, the Abuja Declaration serves as a reminder of the commitment made by African nations to prioritize health and allocate 15% of their national budget towards health financing (2). Many countries are struggling to fulfill this commitment. Equitable and sustainable healthcare financing and access are fundamental for the prosperity of this region and the well-being of its people. By prioritizing health as an investment, we can pave the way for a healthier, more productive, and resilient future. Health investment is fundamental for sustainable development on the continent. Let's join forces to deliver a sustainable, healthy SSA. 1. World Bank. World development report: makings services work for poor people. 2. UN.org. Public financing for health in Africa: 15% of an elephant is not 15% of a chicken.

71

2 Comments

Hypertension impacts 65% to 85% of patients with chronic kidney disease (#CKD) and increases as kidney function declines. On World Hypertension Day, we acknowledge the need to address this pressing health issue. As AstraZeneca’s Healthy Heart Africa (HHA) programme surpasses a key milestone - identifying over 10.8 million individuals with elevated blood pressure in nine countries in Africa - we are re-invigorated to address the overlapping risk of CKD and other non-communicable diseases (#NCDs). This is critical to achieve our vision of creating resilient healthcare systems. To drive this vision forward, we are excited to announce that #AstraZeneca will co-host a high-level event at the 77th World Health Assembly (WHA) in collaboration with the Uganda Ministry of Health to address Africa's growing burden of NCDs. We will share insights on our successful strategies, such as community-based screening and education initiatives, and discuss plans to expand our efforts to include CKD and other NCDs within #HHA while expanding to more countries. On this Day, we renew our commitment to addressing the interconnected challenges of hypertension and CKD. By focusing on building resilient healthcare systems that tackle all patient pathways, from awareness and prevention to evidence-based care, we can improve health outcomes and build a healthier future together for equitable care. #HealthyHeartAfrica #EquityInHealth #WorldHypertensionDay Qutaiba Al Manaseer Deepak Arora Hatem Werdany Maria Nauss Jennifer Jackson Chloe Jolley

148

We are proud to announce that AstraZeneca signed new memorandums of understanding with the Ministry of Health - Uganda, Ministry Of Health, Ghana and Ghana Health Service at the 77th World Health Assembly (#WHA77) last week expanding Healthy Heart Africa. These partnerships further enhance our efforts to tackle chronic kidney disease and other #NCDs through increased education, screening, and treatment initiatives. Together, we aim to make a lasting impact on health outcomes in Africa. Healthy Heart Africa, launched by #AstraZeneca in 2014, has made remarkable progress in addressing hypertension and other noncommunicable diseases (#NCDs),across the continent. With over 50 million people screened and more than 11,480 healthcare workers trained, we're expanding our efforts to combat chronic kidney disease and reach new regions. Read more in my interview with Health Policy Watch discussing the significance of these memorandums on the health ecosystem in Africa while emphasizing the importance of adopting a holistic and comprehensive approach to address the growing burden of #NCDs in Africa. https://lnkd.in/dkG256UD Pelin Incesu Asa Skiti Qutaiba Al Manaseer Ruud Dobber Chloe Jolley Jasper Meyns Bernard Oduor Marcos Ruth Field 🇿🇦 Michael Mangutha Gitangu, M.D. Khomotso Mashilane Nelson Ochieng Margaret Kigwe Dr. William M. Maria Nauss #WHA77 #HealthyHeartAfrica #HealthSystems #NCDs #HealthEquity

180

3 Comments

AstraZeneca’s Healthy Heart Africa programme was established in 2014 as a response to Africa’s increasing burden of cardiovascular diseases. Over the past decade, the programme has expanded into 9 African countries, screening more than 54.4 million people for high blood pressure, training more than 11,480 healthcare workers, and activating 1,516 healthcare facilities to provide hypertension services. These efforts have identified more than 10.8 million people with high blood pressure by mid-2024, while driving patients to diagnosis linked to evidence-based treatment.     In line with AstraZeneca's commitment to promoting health equity and supporting regional strategies and goals, the Healthy Heart Africa programme has evolved to include capacity and capability building, investment in improved screening and diagnostics, and the integration of screening for chronic kidney disease (CKD) to address a broader spectrum of non-communicable diseases (NCDs).    To ensure a comprehensive approach to NCDs, including CKD, AstraZeneca continues to work collaboratively with local, national, and international partners and stakeholders, including government bodies, patient groups, and non-governmental organisations. HHA will expand to new countries in Northern Africa to align with global health objectives and reinforce the programme's commitment to promoting health equity and supporting regional strategies and goals.    Join Us in Building a Healthier Future and learn more about the programme success here: https://lnkd.in/dxcH6R6B    #HealthyHeartAfrica  #NCDs #EquityInHealth Pelin Incesu Qutaiba Al Manaseer Abdulkareem Al Dissi Maria Nauss Grace El Hawa Chloe Jolley

75

"Believe in yourself and dare." These are the words of Hamza Laajaj, @Sanofi’s Manufacturing 4.0 Booster Leader at our Neuville site (France), and a motto we collectively share. At Sanofi, when it comes to manufacturing vaccines to improve people’s lives, we embrace diversity through the roles we play, the projects we work on, and the teams we work with. By being open to diversity, we unlock innovation. Learn more about how Hamza is fueled by collective energy to lead manufacturing innovation in our pursuit of progress. #PursueProgress #Science #Diversity

12

At Celnova Pharma we agree that the future of the pharmaceutical industry is in developing countries and emerging markets, as highlighted in the article on Pharmacy Times by Marcel Gradidge, Vice President of Life Sciences at Capgemini Invent. The article explores the key factors driving this shift, including rising healthcare access, evolving demographics, and the growing middle class. It also highlights the opportunities for collaboration with local governments and institutions. However, navigating the complex regulatory environments and unique challenges of these markets can be daunting. Local know-how is key to success in these dynamic landscapes. #Pharma #Healthcare #EmergingMarkets #LatAm #Biotech #CelnovaPharma #Rarediseases

61

1 Comment

On World Hypertension Day, we must acknowledge that hypertension remains a significant health challenge in Africa, affecting over 150 million adults and is projected to pass the 216 million people mark by 2030 . The interconnected nature of hypertension with other non-communicable diseases, like chronic kidney disease, underscores the urgent need for comprehensive health interventions.   Despite affecting an estimated 15% of people in Africa , higher than the global average, low public awareness and insufficient health policies mean chronic kidney disease often goes undetected and undertreated.   Recognising these gaps, AstraZeneca is co-hosting a high-level event with the Ministry of Health of Uganda at the 77th World Health Assembly (WHA) to discuss the current challenges of cardiorenal diseases and other NCDs while addressing the importance of resilient healthcare systems in improving health outcomes.   The event will include promising announcements on AstraZeneca ‘s Health Heart Africa (HHA) Programme and its upcoming milestones.   Today, we celebrate HHA’s ongoing achievements while looking forward to launching the programme's next chapter at WHA, where we work together through public-private partnerships for equitable and resilient healthcare in Africa.   #WorldHypertensionDay #HealthyHeartAfrica #NCDs #EquityInHealth Pelin Incesu Qutaiba Al Manaseer Ahmed Kishta Basma Shams Chloe Jolley Maria Nauss Dina Khalil Deepak Arora

82

"#ZaZiBoNa: Bridging Regulatory Gaps for Better Health Outcomes" in #SouthernAfrica ZaZiBoNa- Core group countries is Zambia/ Zimbabwe/ Botswana and Namibia, however it is now extended & grown to 16 countries of Africa either as a active, non-active or observer participants based on their internal capacity to conduct joint assessments and joint current Good manufacturing practices inspections. Purpose- The mandate was primarily focused on the harmonization of medicine registrations and was subsequently updated in 2016 to include other regulatory functions. Recent News - SADC joint statement released on 27th October 2023, Cape Town, South Africa for collaborations to conduct joint assessments and joint current Good manufacturing practices inspections. Pilot Project opens in between mid of March or April 2024 to accept 30 dossier from all therapeutic segments. Depends on the acceptability of the dossier, 3 countries joint audit will be scheduled with core member -Zimbabwe followed by 2 or 1 countries MoH health inspector jointly come for the audit ( Mostly Zambia/ Namibia and South Africa). Post successful audit, they will give ZaZiBoNa ( SADC) GMP certificate which will be acceptable to all SADC members with the exceptions South Africa. South Africa comes under WHO GMP group 3 category. Dossier filed under ZaZiBoNa ( SADC) will be accepted as a letter of expression, post approval, they will give letter of recommendations (LoR) against the products and same can be used in 16 countries for drug registration. Benefit of LoR ZaZiBoNa - 1. Quicker registration ( within 2-4 months with basic documents or module -1 or module 2). Product registration fees need to be pay at respective countries MoH. 2. No need of countries specific audit. Fees - $ 18,000.00 ( Includes audit fees/ stay/ travel etc. ). Joint statement signed by - Angola/ Botswana/ Comoros/ DR Congo/ Eswatini/ Lesotho/ Madagascar/ Malawi/ Mauritius/ Mozambique/ Namibia/ Seychelles/ South Africa/ Tanzania/ Zambia/ Zimbabwe.

10

5 Comments

Given that up to 90% of medicines utilized in Africa are imported, there is a substantial opportunity for investors and governments to develop a robust pharmaceutical sector with manufacturing facilities based on the continent. Although there are some challenges such as securing skilled personnel and managing low material availability, the potential for growth and profit remains substantial. Investment opportunities extend beyond hospitality, with the pharmaceutical industry being a particularly promising sector.

2

On World Hypertension Day, we must acknowledge that hypertension remains a significant health challenge in Africa, affecting over 150 million (1) adults and is projected to pass the 216 million people mark by 2030 (2). The interconnected nature of hypertension with other non-communicable diseases, like chronic kidney disease, underscores the urgent need for comprehensive health interventions.   Despite affecting an estimated 15% of people in Africa (3), higher than the global average, low public awareness and insufficient health policies mean chronic kidney disease often goes undetected and undertreated.   Recognising these gaps, @AstraZeneca is co-hosting a high-level event with the Ministry of Health of Uganda at the 77th World Health Assembly (WHA) to discuss the current challenges of cardiorenal diseases and other NCDs while addressing the importance of resilient healthcare systems in improving health outcomes.   The event will include promising announcements on @AstraZeneca’s Health Heart Africa (HHA) Programme and its upcoming milestones.   Today, we celebrate HHA’s ongoing achievements while looking forward to launching the programme's next chapter at WHA, where we work together through public-private partnerships for equitable and resilient healthcare in Africa.   #WorldHypertensionDay #HealthyHeartAfrica #NCDs #EquityInHealth Asa Skiti Hatem Werdany Nelson Ochieng Qutaiba Al Manaseer Chloe Jolley Maria Nauss Pelin Incesu Imran Rashid Bernard Oduor Marcos Michael Mangutha Gitangu, M.D. Dr. William M. Ruth Field 🇿🇦 ________________________________________ 1.  Parati, G., Lackland, D. T., Campbell, N. R. C., Owolabi, M. O., Bavuma, C., Beheiry, H. M., Dzudie, A., Ibrahim, M. M., El Aroussy, W., Singh, S., Varghese, C. V., Whelton, P. K., Zhang, X.-H., & on behalf of the World Hypertension League. (2022). How to improve awareness, treatment, and control of hypertension in Africa, and how to reduce its consequences: A call to action from the World Hypertension League. Hypertension, 79(10), 1949–1961. https://lnkd.in/d8P2V4Vz  2.  Olowoyo, P., Barango, P., Moran, A., Williams, B., Whelton, P. K., Owolabi, M., & on behalf of ACHIEVE. (2024). Priorities to reduce the burden of hypertension in Africa through ACHIEVE. The Lancet Global Health, 12, e192-e204. https://lnkd.in/dC99R5AJ  3. Kaze, A.D., Ilori, T., Jaar, B.G. et al. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. BMC Nephrol 19, 125 (2018). https://lnkd.in/dsC2s28f I’m

94

1 Comment

AstraZeneca’s Healthy Heart Africa programme was established in 2014 as a response to Africa’s increasing burden of cardiovascular diseases. Over the past decade, the programme has expanded into 9 African countries, screening more than 54.4 million people for high blood pressure, training more than 11,480 healthcare workers, and activating 1,516 healthcare facilities to provide hypertension services. These efforts have identified more than 10.8 million people with high blood pressure by mid-2024, while driving patients to diagnosis linked to evidence-based treatment.     In line with AstraZeneca's commitment to promoting health equity and supporting regional strategies and goals, the Healthy Heart Africa programme has evolved to include capacity and capability building, investment in improved screening and diagnostics, and the integration of screening for chronic kidney disease (CKD) to address a broader spectrum of non-communicable diseases (NCDs).    To ensure a comprehensive approach to NCDs, including CKD, AstraZeneca continues to work collaboratively with local, national, and international partners and stakeholders, including government bodies, patient groups, and non-governmental organisations. HHA will expand to new countries in Northern Africa to align with global health objectives and reinforce the programme's commitment to promoting health equity and supporting regional strategies and goals.    Join Us in Building a Healthier Future and learn more about the programme success here: Healthy Heart Africa - Access to Healthcare - AstraZeneca    #HealthyHeartAfrica  #NCDs #EquityInHealth Pelin Incesu Qutaiba Al Manaseer Ahmed Kishta Basma Shams Chloe Jolley Maria Nauss

74

1 Comment

Fresenius Kabi, a subsidiary of Fresenius SE, has announced the availability of Tyenne®, the first tocilizumab biosimilar in the U.S. This biosimilar, 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗳𝗼𝗿 𝗯𝗼𝘁𝗵 𝗶𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗻𝗱 𝘀𝘂𝗯𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝘂𝘀𝗲, offers a more accessible and affordable treatment option for patients with chronic autoimmune diseases. Tyenne®'s launch contributes significantly to Fresenius' (Bio)Pharma platform, aligning with its #FutureFresenius strategy. 𝗧𝘆𝗲𝗻𝗻𝗲® 𝗺𝗮𝗿𝗸𝘀 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀' 𝘁𝗵𝗶𝗿𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗮𝗻𝗱 𝘀𝗲𝗰𝗼𝗻𝗱 𝗶𝗻 𝗶𝘁𝘀 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼. 𝗜𝘁 𝘁𝗿𝗲𝗮𝘁𝘀 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮��𝗲𝘀 𝘀𝘂𝗰𝗵 𝗮𝘀 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗷𝘂𝘃𝗲𝗻𝗶𝗹𝗲 𝗶𝗱𝗶𝗼𝗽𝗮𝘁𝗵𝗶𝗰 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀. Fresenius Kabi's CEO sees Tyenne® as a game-changer in the U.S. healthcare landscape, emphasizing their commitment to expanding patient access to advanced biopharmaceuticals. The company's support program aims to assist healthcare professionals and patients, ensuring broader access to treatment options. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹𝗹𝘆, 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀 𝗞𝗮𝗯𝗶 𝗵𝗮𝘀 𝗮 𝗿𝗼𝗯𝘂𝘀𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗼𝗳 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗮𝗻𝗱 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗶𝘁𝘀 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗶𝗻��𝗼𝘃𝗮𝘁𝗶𝗼𝗻. Fresenius' overarching strategy, #FutureFresenius, focuses on becoming a leading therapy-focused company. #marketintelligence #competitiveintelligence #pharmaceutical #marketsmind #tocilizumab #freseniuskabi

19

1 Comment

Driving Change in Zambia: Roche's Commitment to Breast Cancer We are excited to highlight a significant milestone in our collaboration with the Zambian Ministry of Health to improve cancer outcomes in Zambia. In 2023, Roche and the Zambian Ministry of Health signed a Memorandum of Agreement (MoA) aimed at enhancing the early diagnosis of breast and cervical cancer. On June 25th, in Lusaka, the Permanent Secretary - Technical Services Ministry of Health Zambia, Dr Kennedy Lishimpi, appointed a steering committee to oversee the implementation of our agreement, ensuring that our initiatives effectively reach the patients who need them most. The committee, comprised of key decision-makers and implementers from Laboratory Services to the Director General of Zambia Medicines and Medical Supplies Agency is dedicated to improving the procurement of reagents and treatment. This partnership marks a crucial step towards better healthcare outcomes for the people of Zambia. During this inaugural meeting, the permanent secretary emphasized the importance of accountability and regular check-ins to ensure we deliver on our promises. This commitment was shared in a press statement aired on local television, further underlining the significance of our efforts. We are also thrilled to announce the upcoming Patient Navigation Workshop, aimed at raising awareness for early diagnosis and treatment of Breast Cancer and Cervical Cancer, scheduled for Q3. Additionally, we are finalizing, launching, and rolling out the BC training manual in two pilot provinces. At Roche, we recognize the stark reality: 5 in 10 women diagnosed with breast cancer in Africa today will not be here in 5 years. But it doesn't have to be this way. We have a bold ambition to significantly improve survival rates, aiming for 8 in 10 women in Africa to survive the disease by 2030. This collaboration with Zambia is a crucial step towards achieving this goal. Watch the full press statement here https://lnkd.in/gK9dCGcz Maturin Tchoumi Wendy Cupido Karen Nakawala Paul M Chilwesa, MD FCRO Dr Kennedy Lishimpi paul kamfwa Rachel Chipwende Esnath Muzenda Mirroph Mashego Gift Charles Tomo Taetsane #BreastCancerAwareness #Zambia #RocheAfrica #RocheAfricaPharmaceutical

64

11 Comments

I’m looking forward to joining Africa’s leading CEOs alongside Racey Muchilwa , Hakim Khelifa and Bola Bardet and moderator Kgosietsile II Matthews Mmopi at #ACF2024 tomorrow to discuss the role of the public and private sectors respectively, in driving healthcare investment on the African continent, and the potential for collaboration. Investing in health has already had tangible impacts on African economies. For example, between 2004 and 2018, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) was associated with a 2.1% increase in the GDP growth rate per capita, compared to what would have been expected in the absence of the program. By working together, public-private partnerships can help to expand access to healthcare services, ensuring a healthy workforce that supports the well-being and economic stability of our communities and countries. #ACF2024 #AfricanHealthcare #HealthIsWealth

289

3 Comments

Great to have attended the launch of the African Vaccine Manufacturing Accelerator (AVMA) in Paris today, as part of the GAVI’s Global Forum for Vaccine Sovereignty and Innovation. The international biopharmaceutical industry welcomes the launch of the African AVMA. This is an innovative financial mechanism, that aims to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing For the AVMA to have the maximum possible impact, it is important that it is complemented by creating the right environment to attract sustainable investment and that the broader regulatory, skills and legal frameworks are in place. IFPMA is committed to work with African stakeholders and partners to find solutions to build a sustainable pharmaceutical industry in Africa 👉 Read IFPMA News Release: https://ifpma.info/4ctvPdb #GAVI #AVMA #IFPMA #AfricanUnion #Vaccines #Globalhealth

83

3 Comments

As someone who once led GSK’s strategy and execution from 2007 to 2010 for its respiratory portfolio (Ventolin, Seretide, Flixotide, Flixonase and Avamys) with pioneering initiatives and launches across West English Speaking Africa, I find the situation Nigerian asthma patients find themselves in, following the downturn of their economy resulting in the exit of a number of Big Pharma companies, of very great concern. It cannot be overstated that badly run economies are not only bad for businesses, but are bad for society as well. People have had to make several trade offs, often with very untoward consequences, especially for the less financially endowed. Sometimes, I struggle to believe if our governments and public service institutions believe health is really wealth, as they keep on harping. For me, I see very few national expenditure priorities matching with the societal needs. What kills me most is the wasteful spending, mismanagement and corruption, after all the high taxes! It’s a very unfortunate situation, but I believe we can all do better to improve the lives of our people. We all have a part to play.

65

27 Comments

Pharma Afrique Regulatory News Updates:- 6.4.2024 New Pandemic in The Horizon Says Chinese President Xijing Ping-Africa needs to ACTIVATE its PANDEMIC & EMERGENCY PREPAREDNESS or else we will not have learnt from the Previous COVID 19 ( Corona Virus) devastating pandemic. This could likely be a mutated NEW VIRUS STRAIN. By now, Work should be ongoing & developments of Vaccines & Essential Medicines that will be used for prevention or treatment incase of this outbreak. It will be sad & unbelievable if we didn’t learn lessons from the previous CORONA VIRUS PANDEMIC #PandemicAndEmergencyPreparedness #Covid19 #Vaccines #Essential Medicines #Pandemic #NextPandemic #ChinesePandemic #NewStrain #OutBreak #coronavirus hashtag#ChinesePresident hashtagXijinPing

2